Skip to main content

Table 5 Association of protein expression levels with clinical response and progression-free survival (n = 18)

From: Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma

Phosphorylated targets

Clinical response

Survival

CR

PR

SD ≥ 6 months

SD < 6 months

PD

CBR

P value

Median PFS (95% CI), months

P value

AKT

      

0.367

 

0.597

Negative

0

0

5

2

0

71.4%

 

11.3 (3.858-18.742)

 

Positive

0

1

4

4

2

45.5%

 

5.6 (0.313-10.887)

 

mTOR

      

0.023

 

0.001

Negative

0

0

0

3

1

0%

 

3.7 (2.003-5.397)

 

Positive

0

1

9

3

1

71.4%

 

11.3 (5.250-17.350)

 

S6RP

      

0.069

 

0.002

Negative

0

0

0

2

1

0%

 

3.7 (0.499-6.901)

 

Positive

0

1

9

4

1

66.7%

 

11.3 (6.882-15.718)

 

4EBP1

      

0.617

 

0.160

Negative

0

0

1

2

0

40.0%

 

3.8 (3.640-3.960)

 

Positive

0

1

8

4

2

60.0%

 

8.6 (0.647-16.553)

 
  1. Abbreviations: CR complete response, PD progression of disease, PFS progression-free survival, PR partial response, SD stable disease.